About This Tool

The Nucala (mepolizumab) Dosing Calculator is designed to assist licensed healthcare professionals in determining the appropriate dosage based on the patient’s approved indication and age. This resource simplifies the application of dosing guidelines found in the official Prescribing Information by providing a quick reference for administration schedules. It is intended for educational and clinical support purposes and should not replace professional clinical judgment.

Outputs Explained

After entering the required patient data, the calculator provides a clear, concise summary of the recommended Nucala (mepolizumab) dosing schedule. The output includes:

• Recommended Dose: The precise dose in milligrams (mg) for the specified indication and age group.
• Administration Details: Instructions on how the dose should be administered, such as the number of subcutaneous injections required.
• Dosing Frequency: The recommended interval between each dose, which is typically every 4 weeks.

How to Use the Calculator

To determine the correct dosing regimen, follow these two simple steps:

1. Select Indication: Choose the patient’s condition from the dropdown menu (e.g., Severe Eosinophilic Asthma, EGPA).
2. Enter Patient Age: Input the patient’s age in years into the designated field.

Click “Calculate Dose” to view the results. The “Reset” button will clear all fields for a new calculation.

Dosing Overview

Nucala dosing is specific to the indication and the patient’s age. All doses are administered via subcutaneous injection once every 4 weeks.

• Severe Eosinophilic Asthma (SEA):
  • Adults and adolescents aged 12 years and older: 100 mg.
  • Pediatric patients aged 6 to 11 years: 40 mg.
• Eosinophilic Granulomatosis with Polyangiitis (EGPA):
  • Adults aged 18 years and older: 300 mg (administered as three 100 mg injections).
• Hypereosinophilic Syndrome (HES):
  • Adults and adolescents aged 12 years and older: 300 mg (administered as three 100 mg injections).
• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP):
  • Adults aged 18 years and older: 100 mg.

Switching Therapies

The decision to switch a patient from another biologic to Nucala, or vice versa, requires careful clinical consideration by a specialist. Factors such as disease control, patient preference, and potential for adverse effects should be evaluated. This calculator does not provide guidance on switching; refer to clinical guidelines and the product’s Prescribing Information.

Missed Dose Protocol

If a patient misses a scheduled dose of Nucala, they should be advised to administer it as soon as possible. The subsequent dosing schedule should be adjusted to maintain the 4-week interval from the date of the last injection. Instruct patients to contact their healthcare provider for specific guidance.

Safety Alerts

This tool is for informational purposes only. It is not a substitute for the full Prescribing Information (PI), which contains critical details on warnings, precautions, contraindications, and potential adverse reactions, including hypersensitivity reactions. Healthcare professionals must review the complete PI before prescribing or administering Nucala (mepolizumab).

Frequently Asked Questions (FAQ)

References

• Nucala (mepolizumab) US Prescribing Information – U.S. Food and Drug Administration (FDA)
• Nucala (mepolizumab) European public assessment report (EPAR) – European Medicines Agency (EMA)
• Nucala for Healthcare Professionals – GlaxoSmithKline
• Nucala Professional Drug Information – Drugs.com